Carbenicillin indanyl sodium: Difference between revisions
| Line 11: | Line 11: | ||
==FDA Package Insert== | ==FDA Package Insert== | ||
'''[[Carbenicillin | '''[[Carbenicillin indanyl sodium description|Description]]''' | ||
'''| [[Carbenicillin Indanyl Sodium clinical pharmacology|Clinical Pharmacology]]''' | '''| [[Carbenicillin Indanyl Sodium clinical pharmacology|Clinical Pharmacology]]''' | ||
'''| [[Carbenicillin Indanyl Sodium microbiology|Microbiology]]''' | '''| [[Carbenicillin Indanyl Sodium microbiology|Microbiology]]''' | ||
Revision as of 04:18, 2 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Overview
Category
US Brand Names
GEOCILLIN®
FDA Package Insert
Description | Clinical Pharmacology | Microbiology | Indications and Usage | Contraindications | Warnings and Precautions | Adverse Reactions | Overdosage | Clinical Studies | Dosage and Administration | Compatibility, Reconstitution, and Stability | Directions For Use | How Supplied | Labels and Packages
Mechanism of Action
Carbenicillin exerts its antibacterial activity by interference with final cell wall synthesis of susceptible bacteria. The antibacterial activity of Geocillin is due to its rapid conversion to carbenicillin by hydrolysis after absorption. Though Geocillin provides substantial in vitro activity against a variety of both gram-positive and gram-negative microorganisms, the most important aspect of its profile is in its antipseudomonal and antiproteal activity.[1]
References
- ↑ "GEOCILLIN (CARBENICILLIN INDANYL SODIUM) TABLET, FILM COATED [ROERIG]". Text " accessdate" ignored (help)